Modus Therapeutics Holding AB
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (pu… Read more
Modus Therapeutics Holding AB (MODTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.552x
Based on the latest financial reports, Modus Therapeutics Holding AB (MODTX) has a cash flow conversion efficiency ratio of -0.552x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-5.00 Million) by net assets (Skr9.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Modus Therapeutics Holding AB - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Modus Therapeutics Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Modus Therapeutics Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Modus Therapeutics Holding AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AMEDISYS
BE:ADY
|
0.088x |
|
Solis Minerals Ltd
PINK:SLMFF
|
-0.083x |
|
Asia Pptys Inc
PINK:ASPZ
|
-0.001x |
|
KIMBERLY-CLARK
BE:KMY
|
0.663x |
|
Exro Technologies Inc
OTCQB:EXROF
|
0.254x |
|
Silicon Gaming Inc
PINK:SGIC
|
0.033x |
|
Flexituff Ventures International Limited
NSE:FLEXITUFF
|
0.988x |
|
UNITED PARCEL SVC-B - Dusseldorf Stock Exchang
DU:UPAB
|
0.089x |
Annual Cash Flow Conversion Efficiency for Modus Therapeutics Holding AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Modus Therapeutics Holding AB from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr9.07 Million | Skr-18.07 Million | -1.993x | +71.00% |
| 2024-12-31 | Skr2.14 Million | Skr-14.68 Million | -6.870x | -628.09% |
| 2023-12-31 | Skr17.68 Million | Skr-16.68 Million | -0.944x | -111.23% |
| 2022-12-31 | Skr-2.58 Million | Skr-21.72 Million | 8.404x | +922.46% |
| 2021-12-31 | Skr15.73 Million | Skr-16.08 Million | -1.022x | +1.16% |
| 2020-12-31 | Skr7.00 Million | Skr-7.23 Million | -1.034x | -106.33% |
| 2019-12-31 | Skr-2.69 Million | Skr-43.90 Million | 16.343x | +1075.08% |
| 2018-12-31 | Skr23.90 Million | Skr-40.06 Million | -1.676x | -- |